Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients

Thrombosis Research

Volumn 124, Issue 3, 2009, Pages 300-305

  Daniels, Paul R ^a   McBane, Robert D ^a   Litin, Scott C ^a   Ward, Sue A ^a   Hodge, David O ^a   Dowling, Nicole F ^b   Heit, John A ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Low molecular weight heparin; Mechanical heart valve; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULATION; AORTA VALVE; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CLINICAL DECISION MAKING; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEART VALVE PROSTHESIS; HEMOSTASIS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; POSTOPERATIVE CARE; PRIORITY JOURNAL; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

AGED; ANTICOAGULANTS; COMORBIDITY; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INCIDENCE; MALE; MINNESOTA; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 67649690219     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.01.011     Document Type: Article

References (18)

1. Salem D.N., O'Gara P.T., Madias C., and Pauker S.G. Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2008) 593S-629S
2. Singer D.E., Albers G.W., Dalen J.E., Fang M.C., Go A.S., Halperin J.L., et al. Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2008) 546S-592S
3. Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., and Palareti G. Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (Jun 2008) 160S-198S
4. Tinker J.H., and Tarhan S. Discontinuing anticoagulation therapy in surgical patients with cardiac valve prostheses. JAMA 239 (1978) 738-739
5. Katholi R.E., Nolan S.P., and McGuire L.B. Living with prosthetic heart valves: subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 92 (1976) 162-167
6. Katholi R.E., Nolan S.P., and McGuire L.B. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. Am Heart J 96 (1978) 163-165
7. Douketis J.D., Berger P.B., Dunn A.S., Jaffer A.K., Spyropoulos A.C., Becker R.C., et al. The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (Jun 2008) 299S-339S
8. Kearon C., and Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 336 (1997) 1506-1511
9. Bonow R.O. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease). JACC 48 (2006) 1-148
10. Dunn A., and Turpie A.G.G. Perioperative management of patients on oral anticoagulants: a systematic review. Arch Intern Med 163 (2003) 901-908
11. Eckman M.H., Beshansky J.R., Durand-Zaleski I., Levine H.J., and Pauker S.G. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. Does low risk mean high cost?. JAMA 263 (1990) 1513-1521
12. Douketis J.D., Johnson J.A., and Turpie A.G. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin. Arch Intern Med 164 (2004) 1319-1326
13. Kovacs M.J., Kearon C., Rodger M., Anderson D.R., Turpie A.G., Bates S.M., et al. Single-Arm Study of Bridging Therapy With Low-Molecular-Weight Heparin for Patients at Risk of Arterial Embolism Who Require Temporary Interruption of Warfarin. Circulation 110 (2004) 1658-1663
14. Spandorfer J.M., Lynch S., Weitz H.H., Fertel S., and Merli G.J. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 84 (1999) 478-480
15. Tinmouth A., Morrow B.H., Cruickshank M., Moore P.M., and Kovacs M.J. Dalteparin as periprocedure anticoagulation for patients on warfarin at high risk of thrombosis. Annals of Pharmacotherapy 35 (2001) 669-674
16. Ferreira I., Dos L., Tornos P., Nicolau I., Permanyer-Miralda G., and Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocoumarol. Heart 89 (2003) 527-530
17. Spyropoulos A.C., Turpie A.G.G., Dunn A.S., Spandorfer J., and Douketis J. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 4 (2006) 1246-1252
18. Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (Jun 2008) 381S-453S